The pituitary gland is a heterogeneous tissue comprised of several hormone secreting and supporting cells, most of which are targeted by estrogens. Estrogen-induced changes in the pituitary are presumably mediated via the classical estrogen receptor, ER␣. However, a novel receptor, ER␤, and pituitary-specific truncated estrogen receptor products (TERPs) were recently identified. The objectives of this study were to examine the distribution of these receptors in the rat pituitary and compare their regulation by estradiol in SpragueDawley and the estrogen-sensitive Fischer 344 rats.
minute population (6 -10%) of either anterior or intermediate lobe cells coexpressed ER␣ and ER␤. In the next experiment, Fischer 344 and Sprague-Dawley rats were injected with oil or estradiol for 24 h. Total RNA from dissected anterior and posterior (neurointermediate) pituitaries was subjected to RT-PCR for ER␣, ER␤, or TERPs. Interestingly, ER␣ and ER␤ were unchanged by estradiol in either lobe of the pituitary. In contrast, estradiol increased pituitary TERP messenger RNA levels 4-to 7-fold. A 20-kDa TERP protein was detected by Western blots in the pituitary but not the uterus. There were no differences in the estradiol-induced expression of any of the receptors between the two strains of rats.
We conclude that: 1) ER␤ is expressed in all anterior and intermediate lobe cell types examined, albeit at a lower level than ER␣; 2) no more than 10% of pituitary cells coexpress ER␣ and ER␤; and 3) estradiol markedly increases TERP messenger RNA levels but does not alter the expression of ER␣ or ER␤. We propose that estrogen receptor heterogeneity contributes to the diversity of pituitary cell responsiveness to estrogens. (Endocrinology 139: 3976 -3983, 1998) T HE PITUITARY gland is a heterogeneous tissue consisting of the anterior, intermediate, and neural lobes. The anterior lobe is comprised of five hormone-producing cells and the supporting folliculo-stellate cells. The intermediate lobe contains primarily melanotrophs, whereas pituicytes (astroglial cells) and nerve endings make up the neural lobe. Several pituitary cell types are known targets for estrogens, including lactotrophs (1, 2) , gonadotrophs (3), folliculostellate (4, 5) , and intermediate lobe cells (6, 7) . The classical estrogen receptor (ER␣), which has been localized to most pituitary cells (8) , is thought to mediate the direct effects of estrogen in the pituitary.
As depicted in Fig. 1 , ER␣ is comprised of five functional domains: a DNA binding domain (DBD), a hinge region, a hormone binding domain (HBD), and two transactivation domains (AF-1 and AF-2). Upon ligand activation, the receptor dimerizes, binds to a consensus DNA sequence named the estrogen response element (ERE), and alters gene transcription (reviewed in Refs. 9 and 10). Several ER␣ isoforms have been identified, especially in cancer cells (11, 12) , but their function remains unclear. The rat pituitary expresses truncated estrogen receptor products (TERPs) that have not been detected in other tissues (13) (14) (15) (16) . These receptors are truncated at exon 5 and have two isoforms, TERP1 and TERP2. The more abundant TERP1 has a unique 31-bp sequence, whereas TERP2 contains the same sequence as TERP1 with an additional 66 bp (Fig. 1) . Neither the specific pituitary cells expressing TERP nor its function are known.
Recently, a second estrogen receptor, termed ER␤, was cloned from the rat prostate (17) . ER␤, which has 95% and 55% homology to DBD and HBD of ER␣, respectively (see Fig. 1 ), exhibits high affinity for estradiol and binds to the same ERE as ER␣ (18, 19) . The dissimilarity in the two transactivation domains between ER␣ and ER␤ raises the possibility of a different pattern of gene activation by the two receptors. Because ER␣ and ER␤ can form heterodimers in vitro (20) , they may also act together to regulate gene transcription. Since its discovery, ER␤ expression has been demonstrated in a variety of tissues, including the pituitary gland (18) , but the exact cellular distribution of ER␤ within the pituitary has not been reported.
The pituitary of Fischer 344 (F344) rats is especially sensitive to exogenous estrogens. Prolonged exposure to estrogens results in hyperprolactinemia and formation of prolactinomas in F344, but not in other rat strains (6, (21) (22) (23) . This estrogen sensitivity of F344 rats is pituitary-specific, because their uterus does not undergo unusual changes in response to estrogen. In spite of a significant interest in this rat strain as a model for prolactinoma formation, the mechanism underlying the heightened sensitivity to estrogens is unknown (21, 24) .
The purpose of this work was to determine the cellular distribution of estrogen receptors in the rat pituitary and examine their regulation by estradiol. The objectives were to: 1) identify the specific pituitary cells that express ER␣ and ER␤; 2) determine whether these receptors are coexpressed in the same cell; and 3) compare estrogen regulation of ER␣, ER␤, and TERPs in the pituitaries of F344 and SpragueDawley (SD) rats.
Materials and Methods Animals
All animal studies were performed under an institutionally approved protocol according to the USPHS guide for the Care and Use of Laboratory Animals. F344 and SD female rats (7-8 weeks old), obtained from Zivic-Miller (Zelienpole, PA), were ovariectomized 10 -14 days before an experiment and maintained on a 12-h light-dark schedule. To examine receptor regulation, rats were injected sc with either estradiol (100 g/ kg) or sesame oil and were killed after 24 h. Depending on the experiment, either whole pituitaries or pituitaries dissected into individual anterior and posterior lobes were removed and immediately frozen.
Combined immunocytochemistry/in situ hybridization
Dual immunocytochemistry/in situ hybridization was performed as previously described (4) . Briefly, frozen pituitary sections (10 m) from SD rats were mounted on slides and fixed with 4% paraformaldehyde. All solutions and antibodies were prepared with diethylpyrocarbonatetreated reagents. Sources of the polyclonal antibodies and their dilutions are as follows: PRL (NIH IC-5) at 1:15,000; S100 (a marker for folliculostellate cells; Eastern Acres Biologicals, Southbridge, MA) at 1:500; POMC (a marker for both melanotrophs and corticotrophs; gift from Dr. B. Eipper, John Hopkins University, Baltimore, MD) at 1:1,000; LH no. 15 (gift from Dr. G. Niswender, Colorado State University, Fort Collins, CO) at 1:25,000; and ER␣ 21 (gift from Dr. G. Greene, University of Chicago, Chicago, IL) at 0.5 g/ml. Antibodies were incubated overnight at 4 C. Staining was obtained using biotinylated-secondary antibodies and avidin-biotin-peroxidase complex (ABC kit, Vector Laboratories, Burlingame, CA). Brown color was developed after adding diaminobenzidine for 2 min.
The immunostained sections were subjected to in situ hybridization. The slides were treated with proteinase K, refixed, and incubated with acetic anhydride, as previously described (4). The ER␣ riboprobe was prepared from a 415-bp subclone (1-415 bp) of a rat ER␣ complementary DNA (gift of Dr. M. Shupnik, University of Virginia, Charlottesville, VA). The ER␤ riboprobe was prepared by PCR cloning of a 305-bp segment (941-1246 bp) from rat hypothalamus. Sequencing was performed to confirm specificity. Sense and antisense probes for the two receptors were labeled with 35 S using a Promega (Madison, WI) in vitro transcription kit and were purified on a Sephadex G-50 column. Slides were hybridized at 55 C, using 750,000 cpm of either probe per section, extensively washed and dipped in Kodak NTB2 emulsion (Eastman Kodak, Rochester, NY). After 5 days at 4 C, the photographic emulsion was developed, and the slides were counterstained with hematoxylin.
RT-PCR
Total RNA was isolated from individual anterior or posterior pituitaries using Tri-reagent (Molecular Research Center, Cincinnati, OH), and 5 g were reverse-transcribed using Superscript II reverse transcriptase and random hexamers (Gibco, BRL, Gaithersburg, MD), as previously described (25) . Primer sequences and the expected product sizes were as follows: 1) ER␣: sense primer 5Ј-GGTCCAATTCTGA-CAATCGAGC-3Ј, antisense primer 5Ј-TTTCGTATCCCGCCTTTCA-TC-3Ј with an expected size of 304 bp; 2) TERP: sense primer 5Ј-GCT-TGTTGAACAGCGACCAG-3Ј, antisense primer 5Ј-CTTGTCCAG-GACTCGGTG-3Ј with expected sizes of 366 bp for TERP1 and 432 for TERP2; and 3) ER␤: sense primer 5Ј-AACACTTGCGAAGTCGGCAG-3Ј, antisense primer 5Ј-AACCTCAAAAGAGTCCTTGGTGTG-3Ј with an expected size of 327 bp. Location of primers for the different estrogen receptors is shown in Fig. 1 . All reactions also contained primers for ribosomal protein L19 (RPL19) as an internal control; sense primer 5Ј-AGTAGTCTTAGGCTACAGAAG-3Ј, antisense primer 5Ј-TTCCTT-GGTCTTAGACCTGCG-3Ј with an expected size of 500 bp.
Optimal conditions for PCR were established after varying the RNA concentration, annealing temperature, and cycle number for each set of primers. For ER␣, 300 ng RNA were amplified at 58 C for 28 cycles. For TERPs, 500 ng RNA were amplified at 55 C for 28 cycles. For ER␤, 500 ng RNA were amplified at 62 C for 30 cycles. PCR products were separated on a 1% agarose gel stained with ethidium bromide, photographed, and analyzed by scanning densitometry (Scion Image Software, Frederick, MD).
Western blotting
Pituitary and uterine tissues were removed from control and estradiol-treated rats and immediately frozen. Tissues were homogenized in a buffer (50 mm Tris-HCl (pH 7.5), 150 mm NaCl, 5 mm EDTA) containing protease inhibitors [0.1 mm phenylmethlysulfonylflouride (Sigma, St Louis, MO), 20 mm sodium molybdate (Sigma), and 50 g/ml lima bean trypsin inhibitor (Worthington Biochemical, Freehold, NJ)] and centrifuged at 13,000 ϫ g for 10 min. After protein determination, using a Pierce (Rockford, IL) BCA protein assay, 30 g of proteins were separated by SDS-PAGE (12% separating gel). Recombinant human ER␣ (hER␣) (50 ng), purchased from PanVera (Madison, WI), was used as a positive control. Proteins were transferred to nitrocellulose membranes (Schleicher and Schuell, Keene, NH), followed by Ponceau S staining to verify transfer. After blocking in 2% nonfat milk for 2 h, blots were incubated overnight at 4 C with polyclonal antibody against ER␣ (C1355; gift from Dr. M. Shupnik) at 1:7,500. This antibody was raised against the extreme C-terminus of the receptor protein (16) (see also Fig. 1 ). An ECL kit (Amersham, Arlington Heights, IL) was used to visualize the products.
Data analysis
Four separate sections from 3-4 rats, each immunostained for a pituitary cell type, were used for the determination of ER␣ and ER␤ gene expression, by in situ hybridization. A cell was considered receptorpositive if 5 or more grains were located within the cell perimeter; background levels with the sense probe were 2-3 grains/cell. Approximately 1000 and 600 immunopositive cells (brown staining within the cytoplasm) in the anterior and intermediate lobes, respectively, were counted for each receptor. The percentage of receptor-expressing cells was determined by dividing the number of cells positive for both the receptor and the immunogen by the total number of immunopositive cells. For determination of anterior or intermediate lobe cells that express ER␣ and/or ER␤, 4 separate sections from 3 rats were first immunostained for ER␣ and then subjected to in situ hybridization for ER␤. Determination of receptor expression was done as described above, except that ER␣-expressing cells were identified by brown nuclear stain- ing. In all cases, cell counting was performed by 2-3 investigators, and the values were averaged.
For RT-PCR determination, the density ratio of receptor/RPL19 bands was analyzed for each reaction product, and the results were expressed as percent of control values.
All results are expressed as the mean Ϯ sem. Statistical differences were determined using ANOVA (Sigma Stat 4.0), followed by either Duncan's or Student-Newman-Keuls post hoc tests. Figure 2 shows representative dark-field photomicrographs of rat uterus and ovary subjected to in situ hybridization for ER␣ and ER␤, respectively. As expected, ER␣-expressing cells are abundant in the luminal and glandular epithelia, as well as in the myometrium of the uterus (left panel), whereas ER␤-expressing granulosa cells are apparent within ovarian follicles (right panel). This pattern conforms with published results (17, 26) on the differential expression of the two receptors in these tissues. Sense probes showed no detectable labeling above background (not shown).
Results

Expression of ER␣ and ER␤ in the uterus and ovary
Expression of ER␣ and ER␤ in different pituitary cell types
To compare the expression of ER␣ and ER␤ by specific pituitary cells, we used a combined immunocytochemistry/ in situ hybridization method. Fig. 3 shows cellular details of lactotrophs within the anterior pituitary (left panel) and melanotrophs within the intermediate lobe (right panel) that express each of the receptors; similar data (not shown) were obtained for gonadotrophs, corticotrophs, and folliculostellate cells. The percentage of each cell type that expresses either ER␣ or ER␤ is summarized in Fig. 4 . Approximately 47% and 27% of the lactotrophs express ER␣ and ER␤, respectively, whereas 35% of the corticotrophs express ER␣, and 25% express ER␤. A similar number of folliculo-stellate cells (30 -35%) express either receptor, whereas gonadotrophs had a significantly (P Ͻ 0.05) higher expression of ER␣ (26%) than ER␤ (17%). Within the intermediate lobe, a significantly (P Ͻ 0.05) higher number of melanotrophs express ER␣ (43%) than ER␤ (23%).
Coexpression of ER␣ and ER␤ in pituitary cells
Using a similar approach, we investigated whether both receptors are coexpressed in the same cell. Fig. 5 shows photomicrographs of anterior (left panel) and intermediate (right panel) lobes depicting cells that express ER␣, ER␤, or both. As summarized in Fig. 6, 38% 
Regulation of estrogen receptor expression by estradiol
Optimization of the RT-PCR method was a prerequisite for quantifying receptor regulation by estradiol. Cycle number, RNA amounts, and annealing temperatures were established for each receptor. An example of RT-PCR parameters for TERP1, using total pituitary RNA from estradiol-treated rats, is shown in Fig. 7 . Because optical densities for both RPL19 and TERP1 increased in a linear fashion between 25-30 cycles (Fig. 7, left panel) , 28 cycles were selected for further experiments. The right panel shows that the optical density for both genes was linear up to 500 ng of RNA. Because these results were obtained from a maximally-stimulated pituitary, 500 ng RNA were used in subsequent experiments. Fig. 7 (lower panel) also shows a photograph of PCR products for TERPs in the anterior pituitary, demonstrating a substantial increase in the expression of the two truncated receptors, in response to estradiol. Figure 8 summarizes receptor regulation by estradiol in the anterior and posterior pituitaries from F344 and SD rats. Within 24 h of estradiol treatment, TERP1 mRNA levels rose 5-to 7-fold above controls (P Ͻ 0.05) in either the anterior or posterior pituitaries. The less abundant TERP2 increased 3-to 5-fold above control (P Ͻ 0.05), in response to estradiol in the anterior pituitary, but was not significantly higher than control in the posterior pituitary. Unexpectedly, the expression of ER␣ or ER␤ was not altered by estradiol in either lobe of the pituitary. Although estradiol treatment decreased ER␤ levels in the anterior pituitary of F344 rats to 50% of controls, this change did not reach statistical significance. There were no significant differences between the two strains of rats in the ability of estradiol to induce any of the receptors.
Presence of TERP protein in the pituitary but not the uterus
Because TERP mRNA levels in the pituitary were upregulated by estradiol, we examined whether the truncated receptor is also translated. An antibody directed at the last 18 amino acids of ER␣ (see Fig. 1 ) was used for Western blots of pituitary and uterine proteins. Figure 9 shows the detection of a full-length ER␣ (66 kDa) in the pituitary, uterus, and recombinant hER␣. The TERP protein (20 kDa) was detected in the pituitary, but not uterus, confirming a previous report by Friend et al. (16) . Interestingly, TERP was also detected in a control pituitary, without an apparent increase after estradiol treatment. Another immunoreactive product (approximately 50 kDa) was seen in the estradiol-treated, but not control, uterus.
Discussion
Estrogens affect pituitary function either directly or indirectly via the hypothalamus. To delineate the direct action of estrogen, it is imperative to establish the distribution of its receptors within the pituitary. Previous studies, conducted before the discovery of ER␤, reported estrogen receptor distribution in the pituitary using autoradiography (8), immunocytochemistry (26, 27) , or in situ hybridization (28) . Here we used combined immunocytochemistry and in situ hybridization to compare the distribution of ER␣ and ER␤ in identified pituitary cells and to determine whether any cells coexpress the two receptors. In addition, we investigated whether these receptors are regulated by estradiol.
The lactotrophs, which constitute 25-40% of total anterior pituitary cells (29) , are well recognized as a major target for estrogens. Several lines of evidence established that estrogens increase PRL gene expression, synthesis, storage, and release, as well as lactotroph proliferation (30) . Our data demonstrate that approximately 50% of the lactotrophs express ER␣ whereas less than 30% express ER␤. Given the marked heterogeneity of the lactotrophs, in terms of electrical activity, hormone storage, responsiveness to secretagogues, and morphology (reviewed in Refs. 31 and 32), it is conceivable that certain subpopulations of lactotrophs express little or no estrogen receptors.
Folliculo-stellate cells constitute 25-30% of anterior pitu- itary cells (4) . These cells, which are devoid of classical hormones, form junctional complexes with hormone-secreting cells (33) and may affect their function via paracrine or juxtacrine interactions (34) . Folliculo-stellate cells are likely targeted by estrogen, as exemplified by a rapid increase in c-fos expression (4) and marked structural changes in these cells (5) in response to estrogen. Our results demonstrate, for the first time, that at least one third of the folliculo-stellate cells express ER␣ or ER␤, suggesting a direct action of estradiol on these cells. The reproductive hormones LH and FSH are under positive and negative regulation by estrogens. Although the major consensus is that estrogen primarily alters the release of GnRH, estrogen also induces GnRH receptor gene expression in the gonadotrophs (35) and alters their responsiveness to GnRH (3). Interestingly, the majority of gonadotrophs, which constitute 5-10% of the total anterior pituitary cells (36), do not express estrogen receptors. The paucity of estrogen receptors in the gonadotrophs supports the notion that the main action of estrogen affecting the gonadotrophs is via the hypothalamus.
We and others (7, (37) (38) (39) previously reported that the intermediate lobe mediates estrogen-induced PRL surges and that estrogen treatment in vivo increases PRL regulating factor activity in cultured posterior pituitary cells (6) . Using an oligonucleotide probe against ER␣, Pelletier et al. (28) detected estrogen receptor-expressing cells within both the anterior and intermediate lobes but not the neural lobe. We found that more than 40% of the melanotrophs express ER␣, whereas only 20% express ER␤. It remains to be determined whether the estradiol-induced increase in PRL-regulating factor activity in the intermediate lobe is mediated by either of these receptors. Because the POMC antibody also immunostained the corticotrophs, we examined receptor expression by these cells and found that 20 -30% of the corticotrophs expressed either of the estrogen receptors. However, there is little, if any, evidence for a direct action of estrogen on the function of the corticotrophs.
Our data on the distribution of ER␣-expressing cells agree with previous reports that most pituitary cells express ER␣ 8, 27) . The combined immunocytochemistry/in situ hybridization approach provides high resolution, is well-suited for identifying and enumerating specific cells within an intact pituitary gland, but has some unavoidable limitations in terms of quantitation.
The novel aspect of this investigation is the detection of ER␤ expression in all pituitary cell types examined. It is of interest that Kuiper et al. (18) reported expression of ER␤ in the rat pituitary, as determined by RT-PCR, whereas Couse et al. (40) did not detect its expression in the mouse pituitary using ribonuclease protection assay. The disagreement between these findings could be caused by species variation, because we were unable to detect ER␤ in a mouse pituitary using RT-PCR (Mitchner et al., unpublished observations).
ER␤ is predominantly expressed in tissues such as the ovary (41), prostate (17) , bone (42) , and brain (43, 44) . Although the activated ER␣ and ER␤ seem to bind to the same ERE (18) , it is unclear whether they exhibit distinct, overlapping, synergistic, or antagonistic actions. As determined by a mammalian two hybrid system, ER␣ and ER␤ can form heterodimers (20) , suggesting an alternate signaling pathway by which the two receptors may act. However, such a mechanism requires that the two receptors are coexpressed by the same cell. Using immunocytochemistry for ER␣ and in situ hybridization for ER␤, we found coexpression in a minority (8 -10%) of either anterior or intermediate lobe cells. It is possible that such coexpressors represent only one cell type, i.e. lactotrophs or gonadotrophs. To resolve this issue, a challenging triple-labeling technique, which is presently under development, must be employed.
A ligand may up-or down-regulate its receptors, depending on the tissue and physiological conditions. Shupnik et al. (14) reported that ER␣ mRNA levels increased in the uterus, but decreased in the pituitary, following ovariectomy, whereas estrogen replacement reversed the effect of ovariectomy in both tissues. The same group also discovered the existence of a pituitary-specific truncated ER␣, termed TERP, at both the mRNA (15) and protein (16) levels. The latter finding is of significance because many splice variants of the estrogen receptor, detected primarily in tumors, have not been confirmed at the level of the receptor protein.
The minute size of the rat pituitary, especially the posterior pituitary, necessitates a very sensitive detection method. To this end, we optimized an RT-PCR method for quantifying alterations in receptor expression. We found that TERP expression was significantly increased in response to estradiol, whereas ER␣ was unaltered. Shupnik et al. (14) initially reported an estrogen-induced rise in total pituitary ER mRNA levels that included both the wild-type and TERP. In a subsequent study, the same investigators (16) observed a dramatic increase in TERP mRNA levels in the afternoon of proestrus, presumably caused by the rising estradiol levels. Collectively, these results suggest that the overall increase in ER␣ expression, in response to estradiol, can be attributed to TERP. A lack of effect of estradiol on the levels of immunoreactive ER␣ in the monkey pituitary was also reported (45) . Interestingly, the present study also shows that estradiol did not alter the expression of ER␤ in either the anterior or posterior pituitaries.
The up-regulation of pituitary TERP expression by estradiol raises several issues. The first concerns the identity of cells in which TERP mRNA is induced. This is presently difficult to resolve because of the absence of selective tools, e.g., antibodies or probes, for TERP identification. The second concerns the function(s) subserved by this receptor, which lacks the DBD but may still bind estrogen and form heterodimers with the wild-type receptor. We speculate that TERP acts either as a sink for estrogen or as a dominantnegative regulator of the wild-type receptor. Our preliminary results (Mitchner et al., unpublished observations) indicate that TERP mRNA levels increase in response to estradiol in GH 3 cells, a somatomammotroph cell line. This observation suggests that TERPs are expressed in the lactotroph and provides an excellent cellular model for examining their function(s).
We found no significant differences in receptor regulation by estradiol between the two strains of rats. Thus, the enhanced sensitivity of the F344 pituitary to exogenous estrogens may not be attributed to differences in the level of expression of the estrogen receptor. Instead, it could be caused by differences in receptor signaling involving coactivators or suppressors.
In conclusion, we have shown that ER␣ and ER␤ are expressed, in varying proportions, in all anterior and intermediate lobe cells examined. In general, the expression of ER␤ was lower than ER␣. Only a minor population of cells coexpresses the two receptors. Whereas estradiol did not alter the expression of ER␣ or ER␤, TERP was increased 5-to 8-fold. These results suggest that estrogen receptor heterogeneity contributes to the diversity of pituitary cell responsiveness to estrogen. Further investigations should delineate the exact roles of each of these receptors in activating target genes in specific pituitary cell types.
